• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

NIHR Oxford Health Biomedical Research Centre

Improving brain health: the future in mind

MENUMENU
  • About
    • About
    • Management and core team
    • Our partners
    • Timeline of our key achievements
    • Core facilities
    • Work with us
    • Contact
  • Departments
    • NIHR Oxford Cognitive Health Clinical Research Facility
    • Brain Health Centre
    • Oxford Precision Psychiatry Lab (OxPPL)
    • Oxford Dementia and Ageing Research (OxDARE)
    • Treatment Resistant Depression Clinic
    • Experimental Medicine and Industry Partnership (EMIP)
  • Research Themes
    • Better Sleep
    • Brain Technologies
    • Data Science
    • Dementia
    • Depression Therapeutics
    • Flourishing & Wellbeing
    • Mental Health in Development
    • Molecular Targets
    • Pain
    • Preventing Multiple Morbidities
    • Psychological Treatments
  • COVID-19 Research
    • Overview
    • News
    • COVID-19 & clinical management of mental health issues
  • News & Events
    • News
    • Blog
    • Training & Events
    • Psychiatry department seminars
  • Training Hub
  • Patients & Public
    • About Patient and Public Involvement
    • Shape our research
    • Take part in our research
    • Resources for researchers
    • Resources for the public
    • Patient and Public Involvement Strategy
    • Young people’s involvement
You are here: Home / News / How close are we to finding a cure for Alzheimer’s?

How close are we to finding a cure for Alzheimer’s?

27th June 2017

Theme leads, Professors Clare Mackay and Simon Lovestone, reveal details of the world’s biggest and most in-depth studies into dementia on BBC Radio 4’s World at One. Known as the ‘Deep and Frequent Phenotyping Study’, it is hoped that the broad range of tests on people in their middle ages will open up paths to early diagnosis and offer clues to effective treatments for Alzheimer’s disease before major damage to the brain has been done.

Reporter, Andrew Bomford, visits Older Adults and Dementia theme lead, Professor Mackay, at one of the NIHR Oxford Health BRC’s core facilities – the Oxford Centre for Human Brain Activity (OHBA) (pictured above) – to look in on an MRI scan. It is one of the wide range of tests that is part of the study. Listen to his report for BBC Radio 4’s World at One, 26 June 2017:

https://oxfordhealthbrc.nihr.ac.uk/wp-content/uploads/2017/06/Radio_4_FM-2017-06-26_13-30-15_wato_dementia.mp3

The Deep and Frequent Phenotyping Study is going to do every one of these tests that anybody has ever explored. We’re going to see if any one of them measures change before people have symptoms, and then we’re going to combine them using big data analytics.” Professor Simon Lovestone, Informatics / Digital Health theme lead

In a follow-up report on 27 June 2017 for the World at One, Professor Clare Mackay talks about the big data approach, and Professor Simon Lovestone considers what has been the greatest obstacle to progress so far. Is it our understanding of Alzheimer’s disease, the drugs, or the clinical trials?

Listen to the second report by Andrew Bomford for BBC Radio 4’s World at One, 27 June 2017:

https://oxfordhealthbrc.nihr.ac.uk/wp-content/uploads/2017/06/Alzheimers-reports-27_06_17.mp3

In a cartoon version you’d imagine that people go all the way through their lives performing at a particular level, and then they just start to decline very gradually when they reach a particular age. This is people who would go on to develop disease. And that very early stage of that, the gradient is very, very shallow, so we need really sensitive measures to be able to pick it up.” Professor Clare Mackay

“It might be that everything that we’ve learnt about Alzheimer’s disease is wrong? I don’t think that’s the case. It might be that everything that we know about Alzheimer’s disease is right, it’s just that the drugs are not very good? I don’t think that’s the case either. Or it might be that what we know about Alzheimer’s disease is right, and some of the drugs we’ve developed might work, but the clinical trials are not good enough? I think that’s the case.” Professor Simon Lovestone

The Deep and Frequent Phenotyping Study is a multi-site study, led by Professor Simon Lovestone at the University of Oxford, and is funded by the MRC and NIHR as part of Dementias Platform UK – a UK-wide infrastructure network designed to support large, multicentre studies into dementia.

Read the related BBC Health online article – ‘Spotting the earliest signs of Alzheimer’s‘.

Filed Under: News

Primary Sidebar

Tweets by OxHealthBRC
Follow @OxHealthBRC

Post categories

Footer

Follow us

  • Twitter
  • YouTube

Improving brain health: the future in mind

The National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) is a partnership between Oxford Health NHS Foundation Trust and the University of Oxford.  We are part of the Oxford Academic Health Partners.
Oxford Academic Health Partners
  • Sitemap
  • Accessibility
  • Disclaimer
  • Cookies
  • Contact

© 2023 NIHR Oxford Health Biomedical Research Centre · Log in

Cookies

This site uses cookies: See our privacy policy